Vivos Inc. (OTCQB: RDGL) submits Early Feasibility Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) for RadioGel® Precision Radionuclide Therapy™

Regulatory filing is real, but most upside claims remain unproven and unsupported by data.

What the company is saying

Vivos Inc. is positioning itself as a company on the cusp of a major regulatory breakthrough, emphasizing the submission of its Early Feasibility IDE application to the FDA as a pivotal milestone. The company wants investors to believe that this submission marks a 'significant advancement' in its regulatory journey, building on what it calls 'substantial progress' from a prior February 10, 2026 update. The announcement highlights the inclusion of 'strengthened technical and manufacturing data,' 'additional clinical insights' from an ongoing international human trial, and 'compelling real-world safety data' from over 200 IsoPet® veterinary patients, all framed as evidence of readiness for human clinical studies. However, while these elements are mentioned, the company does not provide any specific data, figures, or outcomes to substantiate the technical or clinical claims, nor does it detail the nature or results of the 'additional clinical insights' or 'updated preclinical evidence.' The tone is highly optimistic and forward-looking, with management projecting confidence in both the regulatory process and the commercial potential of its products, particularly RadioGel® and IsoPet®. Notable individuals such as Dr. Michael Korenko (CEO) and Brad Weeks (President) are named, but their involvement is limited to executive roles within the company, not as external validators or institutional investors. The narrative fits a classic biotech IR strategy: focus on regulatory milestones, hint at broad commercial potential, and downplay the lack of financial or operational detail. Compared to prior communications (which are not available for review), there is no evidence of a shift in messaging, but the language remains aspirational and light on specifics.

What the data suggests

The only concrete numerical disclosure in the announcement is that over 200 IsoPet® veterinary patients have been treated, with the company claiming a favorable safety profile, but without specifying the timeframe, types of tumors, or clinical outcomes. There are no financial figures—no revenue, no expenses, no cash position, no burn rate, and no sales data for IsoPet® or any other product. The announcement does not provide period-over-period comparisons, so it is impossible to assess whether the company’s financial or operational trajectory is improving, flat, or deteriorating. There is also no information on patient enrollment numbers for human trials, nor any data on the progress or results of those trials. The gap between what is claimed (regulatory and technical progress, commercial expansion, and international opportunity) and what is evidenced is substantial: only the FDA application submission and the veterinary patient count are verifiable. Prior targets or guidance are not referenced, so there is no way to determine if the company is meeting its own milestones. The quality of disclosure is poor from a financial analysis perspective, as key metrics are missing and there is no way to compare performance across periods. An independent analyst, looking only at the numbers, would conclude that the company has achieved a regulatory filing and some veterinary use, but that all other claims are unsupported by disclosed data.

Analysis

The announcement's tone is upbeat and emphasizes regulatory progress, but the majority of measurable achievements are limited to the submission of an FDA application and the reporting of real-world safety data from over 200 veterinary patients. While the submission itself is a concrete milestone, many claims about the technology's efficacy, future regulatory advancement, and commercial expansion are forward-looking and lack supporting numerical or operational evidence. The language describing 'significant advancement,' 'substantial progress,' and 'multi-tracked strategy' inflates the narrative relative to the actual disclosed facts. There is no mention of large capital outlays or immediate financial impact, and the only quantifiable data relates to veterinary use, not human clinical or commercial progress. The gap between narrative and evidence is moderate: the company has achieved a regulatory filing, but most future benefits remain unproven and aspirational.

Risk flags

• ●Operational risk is high because the company provides no details on manufacturing capacity, supply chain, or ability to scale if regulatory approval is granted. Without operational metrics, investors cannot assess readiness for commercialization.
• ●Financial disclosure risk is acute: the announcement omits all financial data, including revenue, expenses, cash position, and burn rate. This lack of transparency makes it impossible to evaluate the company’s financial health or runway.
• ●Execution risk is significant, as the majority of claims are forward-looking and contingent on successful FDA review, human clinical trial outcomes, and subsequent regulatory approvals. The company has not demonstrated an ability to deliver on these steps.
• ●Data quality risk is present because the only quantitative evidence is the number of veterinary patients treated, with no breakdown by indication, outcome, or adverse events. The absence of human clinical data is a major gap.
• ●Pattern-based risk is flagged by the use of aspirational language ('significant advancement,' 'substantial progress,' 'multi-tracked strategy') without supporting evidence, which is common in early-stage biotech communications that overstate progress.
• ●Timeline risk is material: while the FDA review period is short, the actual value realization from human clinical trials and commercial adoption is likely years away, with no interim milestones disclosed.
• ●Geographic risk is present due to the mention of international activities in India, but with no detail on regulatory environment, market size, or execution capability in that geography.
• ●Leadership risk is moderate: while the CEO and President are named, there is no evidence of external validation or institutional investment, so management’s confidence is not independently corroborated.

Bottom line

For investors, this announcement means that Vivos Inc. (OTCQB:RDGL) has formally submitted an Early Feasibility IDE application to the FDA—a real and necessary step in the regulatory process, but only the beginning of a long journey toward human clinical validation and commercial success. The company’s narrative is highly optimistic and paints a picture of imminent progress, but the lack of disclosed financials, operational metrics, or human clinical outcomes makes it impossible to verify most of the claims. No external institutional figures are involved, so all validation comes from within the company itself. To change this assessment, Vivos would need to disclose specific human clinical data, detailed financials, or binding commercial agreements. In the next reporting period, investors should look for FDA feedback, enrollment and outcome data from human trials, and any evidence of commercial traction (such as sales figures or clinic adoption rates). At this stage, the information is worth monitoring but not acting on, as the signal is weak and the risks are high. The most important takeaway is that while the regulatory filing is a real milestone, the company’s future value depends entirely on successful execution of multiple unproven steps, none of which are yet supported by disclosed data.

Announcement summary

(OTCQB:RDGL) Vivos Inc. announced the submission of its Early Feasibility IDE application to the FDA. The application includes strengthened technical and manufacturing data, additional clinical insights from the ongoing international human trial, updated preclinical evidence, and real-world safety data from over 200 IsoPet ® veterinary patients. The Company expects to receive FDA feedback or decision within the standard 30-day review period. Vivos Inc. recently participated in the SNMMI 2026 Annual Meeting in Los Angeles (May 30–June 2), engaging with key leaders in nuclear medicine and molecular imaging. The Company continues to execute its multi-tracked strategy, including expanding commercial adoption of IsoPet® in veterinary oncology and advancing non-U.S. clinical research and commercialization opportunities for RadioGel ® through Vivos Scientific India LLP. IsoPet ® is commercially available for veterinary use in certified clinics nationwide. The Company remains committed to working closely with the FDA to initiate early feasibility studies as efficiently as possible.

Disagree with this article?